Forward PE Ratio: 11.50
The forward PE ratio is 11.50 as of Thursday, July 9, 2026.
Forward PE Ratio (11.50) = Close Price ($75.96) / Consensus Forward EPS ($6.54)
SOLV Forward PE Ratio Metrics
FORWARD PE RATIO
11.50
SOLV Competitors' Forward PE Ratio
Solventum Corporation
Market Cap
$13.15B
Forward PE Ratio
11.50
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Solventum Corporation (SOLV) | $13.15B | 11.50 |
| Align Technology, Inc. (ALGN)vs › | $12.76B | 15.36 |
| Revvity, Inc. (RVTY)vs › | $12.60B | 20.86 |
| The Cooper Companies, Inc. (COO)vs › | $13.85B | 15.04 |
| Molina Healthcare, Inc. (MOH)vs › | $12.09B | 45.00 |
| Baxter International Inc. (BAX)vs › | $11.60B | 11.45 |
| DaVita Inc. (DVA)vs › | $14.73B | 15.54 |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.25B | 20.18 |
| Bio-Techne Corporation (TECH)vs › | $11.14B | 36.89 |
| Medpace Holdings, Inc. (MEDP)vs › | $15.29B | 31.31 |
Trailing vs Forward
Trailing P/E
9.2
reported TTM EPS
Forward P/E
11.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.54 implies -20.0% EPS decline vs the reported trailing $8.17.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $75.96 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $6.54 | $6.21 – $6.61 | 10 | 11.6x |
| 2027-12-31 | $7.06 | $6.84 – $7.32 | 10 | 10.8x |
| 2028-12-31 | $7.73 | $3.15 – $10.57 | 6 | 9.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Solventum Corporation (SOLV)?
- The forward PE ratio for SOLV stock is 11.50.
Related Metrics
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson